Treatment of melancholia with tranylcypromine
Abstract
Nine of 12 outpatients meeting DSM-III criteria for melancholia responded to treatment with the monoamine oxidase inhibitor (MAOI) tranylcypromine. Responders were less depressed before treatment and after treatment than were nonresponders. MAOIs appear useful in treating endogenous depressions.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
